S R Lakhani

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype
    Sunil R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 11:5175-80. 2005
  2. ncbi The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
    Sunil R Lakhani
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research and the Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 20:2310-8. 2002
  3. ncbi In-situ lobular neoplasia: time for an awakening
    Sunil R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, and Royal Marsden Hospital, SW3 6JB, London, UK
    Lancet 361:96. 2003
  4. ncbi Microarray and histopathological analysis of tumours: the future and the past?
    S R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    Nat Rev Cancer 1:151-7. 2001
  5. ncbi Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer
    S R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Mary Jean Mitchell Green Building, Chester Beatty Laboratories, Fulham Road, London SW3 6JB, UK
    Mol Pathol 54:281-4. 2001
  6. ncbi Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene
    N Rahman
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Br J Cancer 82:568-70. 2000
  7. ncbi Metaplastic breast carcinomas are basal-like tumours
    J S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Histopathology 49:10-21. 2006
  8. ncbi Basal-like breast carcinomas: clinical outcome and response to chemotherapy
    S Banerjee
    Breast Unit, Royal Marsden Hospital, London, UK
    J Clin Pathol 59:729-35. 2006
  9. ncbi Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast
    C Jones
    Breast Molecular Pathology Group, Department of Histopathology, Royal Free and University College Medical School, University College London, London, United Kingdom
    Am J Pathol 158:207-14. 2001
  10. ncbi Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers
    C L Clarke
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    Br J Cancer 95:515-9. 2006

Detail Information

Publications63

  1. ncbi Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype
    Sunil R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 11:5175-80. 2005
    ..To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients...
  2. ncbi The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
    Sunil R Lakhani
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research and the Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 20:2310-8. 2002
    ..This study evaluates the immunohistochemical profiles of tumors arising in patients with mutations in these genes...
  3. ncbi In-situ lobular neoplasia: time for an awakening
    Sunil R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, and Royal Marsden Hospital, SW3 6JB, London, UK
    Lancet 361:96. 2003
  4. ncbi Microarray and histopathological analysis of tumours: the future and the past?
    S R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    Nat Rev Cancer 1:151-7. 2001
    ..But how did the traditional methods of cancer diagnosis and prognosis develop, and how can high-throughput techniques contribute?..
  5. ncbi Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer
    S R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Mary Jean Mitchell Green Building, Chester Beatty Laboratories, Fulham Road, London SW3 6JB, UK
    Mol Pathol 54:281-4. 2001
    ....
  6. ncbi Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene
    N Rahman
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
    Br J Cancer 82:568-70. 2000
    ..Four polymorphisms were detected but no pathogenic mutations were identified. The results indicate that E-cadherin is unlikely to act as a susceptibility gene for LCIS...
  7. ncbi Metaplastic breast carcinomas are basal-like tumours
    J S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Histopathology 49:10-21. 2006
    ..Our aim was to analyse a series of metaplastic breast carcinomas (MBCs) using this panel plus two other basal markers (CK14 and p63) and progesterone receptor (PR), to define how frequently MBCs show a basal-like immunophenotype...
  8. ncbi Basal-like breast carcinomas: clinical outcome and response to chemotherapy
    S Banerjee
    Breast Unit, Royal Marsden Hospital, London, UK
    J Clin Pathol 59:729-35. 2006
    ..Standard adjuvant chemotherapy seems to be less effective in these tumours and new therapeutic approaches are indicated...
  9. ncbi Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast
    C Jones
    Breast Molecular Pathology Group, Department of Histopathology, Royal Free and University College Medical School, University College London, London, United Kingdom
    Am J Pathol 158:207-14. 2001
    ..These alterations are also commonly seen in nonapocrine breast cancer. The data are consistent with apocrine hyperplasia as a putative nonobligate precursor of apocrine carcinoma...
  10. ncbi Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers
    C L Clarke
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    Br J Cancer 95:515-9. 2006
    ..We also confirm and extend our original observation of loss of the wild-type BRCA1 allele in some clones, and loss of the mutant allele in others, demonstrating that loss of either allele is a stochastic event...
  11. ncbi Breast cancer special types: why bother?
    J S Reis-Filho
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    J Pathol 216:394-8. 2008
    ..Here we review the molecular characteristics of special types of breast cancer, with special emphasis on their microarray-based expression profiles and their impact on our understanding of breast cancer...
  12. ncbi Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
    R L Jones
    Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK, and Molecular and Cellular Pathology, School of Medicine, University of Queensland, Mayne Medical School, Herston, Australia
    Br J Cancer 94:358-62. 2006
    ....
  13. ncbi Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
    L G Fulford
    The Breakthrough Breast Cancer Research Centre, London, UK
    Histopathology 49:22-34. 2006
    ..Currently, they are not identified in routine practice and no morphological guidelines exist to aid their identification. The aim of this study was to analyse the histological features of CK14+ IDC...
  14. ncbi High level expression of differentially localized BAG-1 isoforms in some oestrogen receptor-positive human breast cancers
    M Brimmell
    Ludwig Institute for Cancer Research, Imperial College of Medicine, St Mary s Campus, London, UK
    Br J Cancer 81:1042-51. 1999
    ..These results demonstrate a close association between BAG-1 and functional ER expression and suggest BAG-1 may be useful as a therapeutic target or prognostic marker in breast cancer...
  15. ncbi cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells
    Alan Mackay
    LICR UCL Breast Cancer Laboratory, University College London, London, UK
    Oncogene 22:2680-8. 2003
    ..These data represent profiles of the transcriptional changes associated with ERBB2-related pathways in the breast, and identify novel and potentially useful targets for prognosis and therapy...
  16. ncbi Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis
    Peter T Simpson
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Am J Surg Pathol 29:734-46. 2005
    ..These data further support the hypothesis that CCLs are a nonobligate, intermediary step in the development of some forms of low grade in situ and invasive carcinoma...
  17. ncbi Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations
    S R Lakhani
    Department of Histopathology, Royal Marsden Hospital NHS Trust, Sutton, Surrey, United Kingdom
    Lab Invest 74:129-35. 1996
    ..The significance of AI in the pathogenesis of HUT or its subsequent progression to carcinoma is not yet clear and requires further investigation...
  18. ncbi Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)
    M O Leach
    MARIBS Study Office, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Lancet 365:1769-78. 2005
    ..Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening...
  19. ncbi The molecular genetics of breast cancer: the contribution of comparative genomic hybridization
    Jorge S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Pathol Res Pract 201:713-25. 2005
    ..CGH has been instrumental in dissecting distinct molecular pathways toward breast malignancy and in establishing a direct relationship between genotype and clinical pathological features...
  20. ncbi Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes
    Chris Jones
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Clin Cancer Res 10:5988-97. 2004
    ..Robust characterization of this basal group is necessary if it is to have a major impact on management of patients with breast cancer...
  21. ncbi Cytokeratin 5/6 in normal human breast: lack of evidence for a stem cell phenotype
    Catherine L Clarke
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 204:147-52. 2004
    ..This study brings into question the previously described profile of breast 'stem cells' based on CK5/6 staining and hence the breast cancer progression model and classification based on this phenotype...
  22. ncbi Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer
    Chris Jones
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Res 64:3037-45. 2004
    ..These data provide a framework for the interpretation of breast cancer molecular profiling experiments, the identification of potential new diagnostic markers, and development of novel indicators of prognosis...
  23. ncbi Pathology of ovarian cancers in BRCA1 and BRCA2 carriers
    Sunil R Lakhani
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 10:2473-81. 2004
    ..Our aim was to evaluate the morphologies and immunophenotypes in a large cohort of patients with familial ovarian cancer...
  24. ncbi Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity
    Jorge S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK
    J Pathol 207:1-13. 2005
    ..Taken together, these data suggest that at least some PLCs may evolve from the same precursor or through the same genetic pathway as classic lobular carcinomas...
  25. ncbi Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue
    Peter T Simpson
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 202:274-85. 2004
    ..This analysis demonstrates the utility of 14-3-3sigma as a new adjunct antibody for characterization of myoepithelial cells and myoepithelial lesions and it may be a novel prognostic factor for breast cancer patients...
  26. ncbi FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
    Jorge Sergio Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 12:6652-62. 2006
    ..However, little is known about the putative therapeutic targets for these tumors. The aim of this study was to characterize CLCs at the molecular genetic level and identify putative therapeutic targets...
  27. ncbi The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions
    Jorge S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Breast Cancer Res 5:313-9. 2003
    ..We review current knowledge and the contribution of molecular genetics in the understanding of breast cancer precursors and pre-invasive lesions...
  28. ncbi Pathologic quiz case: a 62-year-old woman with a 4.5-cm nodule in the right breast. Lipid-rich breast carcinoma
    Jorge S Reis-Filho
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Arch Pathol Lab Med 127:e396-8. 2003
  29. ncbi The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ
    Peter T Simpson
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Breast Cancer Res 5:258-62. 2003
    ..LCIS is now considered a risk factor and a non-obligate precursor for the subsequent development of invasive cancer...
  30. ncbi Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
    Jorge S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Breast Cancer Res 7:R1028-35. 2005
    ..We investigated whether HER2 and EGFR overexpression was present and evaluated gene amplification in a series of metaplastic breast carcinomas...
  31. ncbi Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
    A E Ring
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Br J Cancer 91:2012-7. 2004
    ....
  32. ncbi The mammary myoepithelial cell--Cinderella or ugly sister?
    S R Lakhani
    Breast Molecular Pathology Laboratory, Department of Histopathology, Royal Free and University College Medical School, London, UK
    Breast Cancer Res 3:1-4. 2001
    ..This review presents our perspective on its broader biological significance and its potential use as a model system for understanding breast carcinogenesis...
  33. ncbi Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast
    J G Stone
    Section of Cancer Genetics, Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, UK
    Cancer Lett 167:171-4. 2001
    ..The other mutation detected in MLH1 was a TAC-->TAA substitution codon 750 (exon 19) creating a stop codon, predicted to generate a truncated protein. These findings suggest that mutations in MLH1 may underlie a subset of LCIS cases...
  34. ncbi EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
    J S Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 209:445-53. 2006
    ..2...
  35. ncbi The inframammary fold: contents, clinical significance and implications for immediate breast reconstruction
    G P H Gui
    Department of Academic Surgery Breast Unit, Royal Marsden NHS Trust, London, UK
    Br J Plast Surg 57:146-9. 2004
    ..If IMF tissue is resected and the immediate breast reconstruction is performed, the superficial fascial system should be reconstructed after excision of the IMF tissue in order to recreate the inframammary crease...
  36. ncbi Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast
    Chris Jones
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 199:152-6. 2003
    ..The limited data from these experiments do not reveal a specific predisposition locus...
  37. ncbi Molecular evolution of breast cancer
    Peter T Simpson
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 205:248-54. 2005
    ..However, only through the combination of comprehensive morphological analysis and cutting-edge molecular tools can this knowledge be translated into clinical practice and patient management...
  38. ncbi Expression profiling using cDNA microarrays
    Chris Jones
    The Breakthrough Toby Robins Breast Research Centre at the Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    Methods Mol Med 120:403-14. 2006
    ....
  39. ncbi Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group
    W D Dunsmuir
    CRC Section of Cancer Genetics and Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 78:1430-3. 1998
    ..We conclude that the incidence of allelic imbalance at HPC1 is low in both sporadic tumours and small prostate cancer families. In this group of patients, HPC1 is unlikely to be acting as a TSG in the development of prostate cancer...
  40. ncbi Collagenous spherulosis in an adenomyoepithelioma of the breast
    J S Reis-Filho
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB UK
    J Clin Pathol 57:83-6. 2004
    ..Antibodies to the oestrogen receptor, progesterone receptor, p63, and c-kit (CD117) proved to be useful adjuncts to differentiate between these lesions...
  41. ncbi The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas
    P J Biggs
    Molecular Carcinogenesis Section, Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, UK
    Oncogene 12:1375-7. 1996
    ..We have also demonstrated LOH using markers on chromosome 16q in 8/14 (57%) sporadic cylindromas, indicating that the cyld1 gene is likely to be involved in the genesis of both familial and sporadic cylindromas...
  42. ncbi Gene expression analysis using filter cDNA microarrays
    Peter Simpson
    The Breakthrough Toby Robins Breast Research Centre at the Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    Methods Mol Med 120:415-24. 2006
    ..This chapter provides an overview of the methods necessary to carry out the production of membrane-based cDNA arrays and the subsequent synthesis and hybridization of radiolabeled cDNA probes...
  43. ncbi Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival
    Laura G Fulford
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res 9:R4. 2007
    ..Previous studies have suggested that expression of such 'basal' markers predicts different biological behaviour, with more frequent lung and brain metastases and poorer prognosis than other carcinomas...
  44. ncbi Identification of the familial cylindromatosis tumour-suppressor gene
    G R Bignell
    1 Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Nat Genet 25:160-5. 2000
    ..CYLD also has sequence homology to the catalytic domain of ubiquitin carboxy-terminal hydrolases (UCH)...
  45. ncbi Pathologic quiz case: a 93-year-old woman with an enlarged and tender left breast. Histiocytoid variant of lobular breast carcinoma
    Jorge S Reis-Filho
    Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, England
    Arch Pathol Lab Med 127:1626-8. 2003
  46. ncbi Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?
    Paul K Lovelock
    Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Herston Road, Queensland 4029, Australia
    Breast Cancer Res 9:R82. 2007
    ....
  47. ncbi Mutation analysis of five candidate genes in familial breast cancer
    Anna Marsh
    Cancer and Cell Biology, Queensland Institute of Medical Research, c o RBH Post Office, Herston, Brisbane, QLD, 4029, Australia
    Breast Cancer Res Treat 105:377-89. 2007
    ..Although we identified many novel variants, we found no evidence that highly penetrant germline mutations in these five genes contribute to familial breast cancer susceptibility...
  48. ncbi Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators
    Amanda B Spurdle
    Queensland Institute of Medical Research, c o Royal Brisbane Hospital Post Office, Herston, Queensland 4029, Australia
    J Clin Oncol 26:1657-63. 2008
    ..We assessed the value of tumor immunohistochemical markers in conjunction with genetic and evolutionary approaches for investigating the clinical significance of unclassified variants...
  49. ncbi Aberrant expression of E-cadherin in lobular carcinomas of the breast
    Leonard Da Silva
    Molecular and Cellular Pathology, Mayne Medical School, University of Queensland, Brisbane, Australia
    Am J Surg Pathol 32:773-83. 2008
    ..Misclassification of tumors may lead to mismanagement of patients in clinical practice, particularly in the context of in situ disease at margins...
  50. ncbi The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?
    Sunil R Lakhani
    Molecular and Cellular Pathology, School of Medicine, The University of Queensland, Mayne Medical School, Brisbane, QLD 4006, Australia
    Eur J Cancer 42:2205-11. 2006
    ..In this review, the working group on behalf of EUSOMA has attempted to summarise the current thinking and management of this interesting lesion...
  51. ncbi Myoepithelial cells: pathology, cell separation and markers of myoepithelial differentiation
    Catherine Clarke
    Molecular and Cellular Pathology, Mayne Medical School, Queensland Institute of Medical Research and The Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, QLD, Australia
    J Mammary Gland Biol Neoplasia 10:273-80. 2005
    ..These immunohistochemical data, combined with genomic studies, may lead to better identification and management of patients with 'basal' tumors...
  52. ncbi The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours
    Elinor J Sawyer
    Molecular and Population Genetics Laboratory, Imperial Cancer Research Fund, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    J Pathol 196:437-44. 2002
    ..In the progression to malignancy, the stromal proliferation appears to become independent of the Wnt pathway and, presumably, of the epithelial component of these tumours...
  53. ncbi Typical medullary breast carcinomas have a basal/myoepithelial phenotype
    Jocelyne Jacquemier
    Marseille Cancer Institute, Molecular Oncology Department, UMR599 INSERM and Paoli Calmettes Institute, Marseille, France
    J Pathol 207:260-8. 2005
    ..In multivariate analysis with logistic regression, TMBC was defined by the association of P-cadherin (R=2.29), MIB1 > 50 (R=3.80), ERBB2 negativity (R=2.24) and p53 positivity (RR=1.45)...
  54. ncbi What's in a cancer syndrome? Genes, phenotype and pathology
    Nicola Wayte
    The Queensland Institute of Medical Research, Brisbane, Australia
    Pathology 40:247-59. 2008
    ....
  55. ncbi Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis
    Ruth M L Warren
    Department of Radiology, Addenbrooke's Hospital, Cambridge, England
    Radiology 236:779-88. 2005
    ..Interreader correlation was moderately good, and evidence of learning was seen. Equipment manufacturer, field strength, and age affected specificity but not sensitivity...
  56. ncbi The diagnosis and management of pre-invasive breast disease--current challenges, future hopes
    Sunil R Lakhani
    Breast Cancer Res 5:248-9. 2003
  57. ncbi In situ carcinoma - can we predict which patient will come back with a recurrence?
    Peter T Simpson
    Molecular and Cellular Pathology, School of Medicine, University of Queensland, Herston QLD 4006, Australia
    Cancer Cell 12:409-11. 2007
    ..In this issue of Cancer Cell, Gauthier and colleagues suggest that abrogated response to cell stress measured by analysis of p16 and the proliferation marker Ki67 accurately predicts recurrence in ductal carcinoma in situ...
  58. ncbi Can the stroma provide the clue to the cellular basis for mammographic density?
    Ruth Warren
    Department of Radiology, Addenbrooke s Hospital, Cambridge, UK
    Breast Cancer Res 5:225-7. 2003
    ..In a paper in this issue of Breast Cancer Research, Alowami has shown a relationship between density and stromal proteins, which might provide useful insight into mammographic density...
  59. ncbi Evaluation of a prospective scoring system designed for a multicenter breast MR imaging screening study
    Ruth M L Warren
    Department of Radiology, Addenbrooke's Hospital, Cambridge, England, and Department of Radiology, University of Aberdeen, Aberdeen, Scotland
    Radiology 239:677-85. 2006
    ..In the context of screening, quantitative enhancement parameters appear to be less useful for lesion characterization...
  60. ncbi Progesterone receptor-positive eruptive syringoma associated with diabetes
    Penelope C Timpanidis
    Department of Dermatology, University College London Hospitals Trust, United Kingdom
    J Am Acad Dermatol 48:S103-4. 2003
    ..We report a case in which eruptive syringoma with clear cell morphology was found to express progesterone receptors, suggesting the possibility of hormonal control of the tumor...
  61. ncbi A test of performance of breast MRI interpretation in a multicentre screening study
    Ruth Warren
    Department of Radiology, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
    Magn Reson Imaging 24:917-29. 2006
    ..Scoring systems developed on one equipment software may not be transferable to other manufacturers...
  62. ncbi Malignant adenomyoepithelioma of the breast metastasizing to the liver
    Chris Jones
    Virchows Arch 442:504-6. 2003
  63. ncbi Somatic mutations of the protein kinase gene family in human lung cancer
    Helen Davies
    The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, United Kingdom
    Cancer Res 65:7591-5. 2005
    ..The results suggest that several mutated protein kinases may be contributing to lung cancer development, but that mutations in each one are infrequent...